Blog

Fibrocell’s gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 … – Seeking Alpha

Fibrocell's gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 …
Seeking Alpha
Thinly traded nano cap Fibrocell Science (NASDAQ:FCSC) perks up 9% premarket on light volume in response to its announcement that the FDA has granted Rare Pediatric Disease Designation to Orphan Drug-tagged FCX-013, a gene therapy candidate for …
Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaGlobeNewswire (press release)


Analysts Offer Predictions for Fibrocell Science Inc's FY2020 Earnings (FCSC)BBNS

all 2 news articles »

2017-06-12 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.